Milestone Scientific (MLSS) Announces Breakthrough CompuPulse System and Receives Notice of Allowance for U.S. Patent
- U.S. stocks close down on news of Biden tax proposal
- Biden To Propose Capital Gains Tax As High As 43.4% For Wealthy - Bloomberg
- Intel (INTC) Tops Q1 EPS by 24c, Offers Guidance
- Snap (SNAP) Tops Q1 EPS by 5c, DAUs were 280 million, Offers Guidance
- Credit Suisse (CS) Falls 6% on 'Unacceptable Loss' as Exposure to Archegos Grew to More Than $20 Billion, Set to Raise Over $2 Billion to Support Liquidity
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its new CompuPulse System, which integrates the Company’s CompuWave™ technology with a manual syringe.
Mark Hochman, D.D.S., Inventor and Clinical Director for Milestone Scientific, commented, "We are pleased to receive this Notice of Allowance related to our new CompuPulse System, which combines the benefits of our CompuWave technology with a manual syringe. Importantly, the new CompuPulse System allows one to identify a pulsatile pressure waveform in a variety of applications, thereby improving the reliability and safety of a drug delivery procedure. Importantly, not all procedures require the sophistication of our CompuFlo system, which precisely controls the administration and flow rate of medication as it is being administered. This new technology provides an efficient and low cost alternative for procedures where a manual syringe may suffice, while still providing the ability to verify needle and subsequent catheter placement.”
Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, stated, “This Notice of Allowance significantly expands the intellectual property surrounding our injection and drug delivery systems and, in turn, further solidifies our leadership position in the computerized injection market. We believe that the combination of the CompuWave technology with the lower cost of a manual syringe opens up a number of exciting new markets and applications for our technology, while still ensuring precise confirmation of needle placement and verification that a catheter has not been displaced during or after a procedure.”
The Notice of Allowance relates to a method and an apparatus that detects a pulsatile pressure waveform to more easily perform the identification of anatomical target regions. The pulsatile waveform is representative of the detection of pressures that are produced by the cardio-vascular system either directly or indirectly. This same system can be used to aid in the determination of the patency of a catheter and to assist in determining if a catheter has been displaced during a procedure.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Olo (OLO) and DoorDash (DASH) Sign Multi-Year Agreement, Settle and Dismiss Contract Dispute
- People's United Bank (PBCT) Tops Q1 EPS by 3c
- Colony Bankcorp (CBAN) to acquire SouthCrest Financial
Create E-mail Alert Related CategoriesCorporate News, Litigation, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!